Cargando…

Exploiting Prophage-Mediated Lysis for Biotherapeutic Release by Lactobacillus reuteri

Lactobacillus reuteri has the potential to be developed as a microbial therapeutic delivery platform because of an established safety profile, health-promoting properties, and available genome editing tools. Here, we show that L. reuteri VPL1014 exhibits a low mutation rate compared to other Gram-po...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexander, Laura M., Oh, Jee-Hwan, Stapleton, Donald S., Schueler, Kathryn L., Keller, Mark P., Attie, Alan D., van Pijkeren, Jan-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498169/
https://www.ncbi.nlm.nih.gov/pubmed/30683744
http://dx.doi.org/10.1128/AEM.02335-18
_version_ 1783415590733479936
author Alexander, Laura M.
Oh, Jee-Hwan
Stapleton, Donald S.
Schueler, Kathryn L.
Keller, Mark P.
Attie, Alan D.
van Pijkeren, Jan-Peter
author_facet Alexander, Laura M.
Oh, Jee-Hwan
Stapleton, Donald S.
Schueler, Kathryn L.
Keller, Mark P.
Attie, Alan D.
van Pijkeren, Jan-Peter
author_sort Alexander, Laura M.
collection PubMed
description Lactobacillus reuteri has the potential to be developed as a microbial therapeutic delivery platform because of an established safety profile, health-promoting properties, and available genome editing tools. Here, we show that L. reuteri VPL1014 exhibits a low mutation rate compared to other Gram-positive bacteria, which we expect will contribute to the stability of genetically modified strains. VPL1014 encodes two biologically active prophages, which are induced during gastrointestinal transit. We hypothesized that intracellularly accumulated recombinant protein can be released following bacteriophage-mediated lysis. To test this, we engineered VPL1014 to accumulate leptin, our model protein, inside the cell. In vitro prophage induction of recombinant VPL1014 released leptin into the extracellular milieu, which corresponded to bacteriophage production. We also employed a plasmid system that does not require antibiotic in the growth medium for plasmid maintenance. Collectively, these data provide new avenues to exploit native prophages to deliver therapeutic molecules. IMPORTANCE Lactic acid bacteria (LAB) have been explored as potential biotherapeutic vehicles for the past 20 years. To secrete a therapeutic in the extracellular milieu, one typically relies on the bacterial secretion pathway, i.e., the Sec pathway. Overexpression of a secreted protein can overload the secretory pathway and impact the organism’s fitness, and optimization of the signal peptide is also required to maximize the efficiency of the release of mature protein. Here, we describe a previously unexplored approach to release therapeutics from the probiotic Lactobacillus reuteri. We demonstrate that an intracellularly accumulated recombinant protein is released following prophage activation. Since we recently demonstrated that prophages are activated during gastrointestinal transit, we propose that this method will provide a straightforward and efficient approach to deliver therapeutics in vivo.
format Online
Article
Text
id pubmed-6498169
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-64981692019-05-21 Exploiting Prophage-Mediated Lysis for Biotherapeutic Release by Lactobacillus reuteri Alexander, Laura M. Oh, Jee-Hwan Stapleton, Donald S. Schueler, Kathryn L. Keller, Mark P. Attie, Alan D. van Pijkeren, Jan-Peter Appl Environ Microbiol Meeting Presentation Lactobacillus reuteri has the potential to be developed as a microbial therapeutic delivery platform because of an established safety profile, health-promoting properties, and available genome editing tools. Here, we show that L. reuteri VPL1014 exhibits a low mutation rate compared to other Gram-positive bacteria, which we expect will contribute to the stability of genetically modified strains. VPL1014 encodes two biologically active prophages, which are induced during gastrointestinal transit. We hypothesized that intracellularly accumulated recombinant protein can be released following bacteriophage-mediated lysis. To test this, we engineered VPL1014 to accumulate leptin, our model protein, inside the cell. In vitro prophage induction of recombinant VPL1014 released leptin into the extracellular milieu, which corresponded to bacteriophage production. We also employed a plasmid system that does not require antibiotic in the growth medium for plasmid maintenance. Collectively, these data provide new avenues to exploit native prophages to deliver therapeutic molecules. IMPORTANCE Lactic acid bacteria (LAB) have been explored as potential biotherapeutic vehicles for the past 20 years. To secrete a therapeutic in the extracellular milieu, one typically relies on the bacterial secretion pathway, i.e., the Sec pathway. Overexpression of a secreted protein can overload the secretory pathway and impact the organism’s fitness, and optimization of the signal peptide is also required to maximize the efficiency of the release of mature protein. Here, we describe a previously unexplored approach to release therapeutics from the probiotic Lactobacillus reuteri. We demonstrate that an intracellularly accumulated recombinant protein is released following prophage activation. Since we recently demonstrated that prophages are activated during gastrointestinal transit, we propose that this method will provide a straightforward and efficient approach to deliver therapeutics in vivo. American Society for Microbiology 2019-05-02 /pmc/articles/PMC6498169/ /pubmed/30683744 http://dx.doi.org/10.1128/AEM.02335-18 Text en Copyright © 2019 Alexander et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Meeting Presentation
Alexander, Laura M.
Oh, Jee-Hwan
Stapleton, Donald S.
Schueler, Kathryn L.
Keller, Mark P.
Attie, Alan D.
van Pijkeren, Jan-Peter
Exploiting Prophage-Mediated Lysis for Biotherapeutic Release by Lactobacillus reuteri
title Exploiting Prophage-Mediated Lysis for Biotherapeutic Release by Lactobacillus reuteri
title_full Exploiting Prophage-Mediated Lysis for Biotherapeutic Release by Lactobacillus reuteri
title_fullStr Exploiting Prophage-Mediated Lysis for Biotherapeutic Release by Lactobacillus reuteri
title_full_unstemmed Exploiting Prophage-Mediated Lysis for Biotherapeutic Release by Lactobacillus reuteri
title_short Exploiting Prophage-Mediated Lysis for Biotherapeutic Release by Lactobacillus reuteri
title_sort exploiting prophage-mediated lysis for biotherapeutic release by lactobacillus reuteri
topic Meeting Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498169/
https://www.ncbi.nlm.nih.gov/pubmed/30683744
http://dx.doi.org/10.1128/AEM.02335-18
work_keys_str_mv AT alexanderlauram exploitingprophagemediatedlysisforbiotherapeuticreleasebylactobacillusreuteri
AT ohjeehwan exploitingprophagemediatedlysisforbiotherapeuticreleasebylactobacillusreuteri
AT stapletondonalds exploitingprophagemediatedlysisforbiotherapeuticreleasebylactobacillusreuteri
AT schuelerkathrynl exploitingprophagemediatedlysisforbiotherapeuticreleasebylactobacillusreuteri
AT kellermarkp exploitingprophagemediatedlysisforbiotherapeuticreleasebylactobacillusreuteri
AT attiealand exploitingprophagemediatedlysisforbiotherapeuticreleasebylactobacillusreuteri
AT vanpijkerenjanpeter exploitingprophagemediatedlysisforbiotherapeuticreleasebylactobacillusreuteri